Semaglutide in CFRD

Completed · Phase 2/Phase 3

Conditions studied: Cystic Fibrosis, Cystic Fibrosis-related Diabetes

In brief

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Key facts

Study ID
NCT05788965
Run by
University of Minnesota
People needed
8
Starts
2023-10-16
Expected to finish
2024-12-31
Last updated by the study team
2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.